Back to results
US 9,872,921 B2Granted
DE-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
AssigneeChildren's Hospital & Research Center at Oakland
InventorsGregory R. Moe, Charles Paul Plested
Life of this patent
Estimating the term…
Abstract
The present invention generally provides compositions methods and composition relating to the diagnosis and/or treatment of cancers having a cell surface de-N-acetylated sialic acid antigen, e.g., an at least partially de-N-acetylated ganglioside and/or a de-N-acetylated sialic acid-modified cell surface protein.
Claims31
An antibody conjugate, comprising:
- an antibody that specifically binds a de-N-acetylated sialic acid (deNAc SA) epitope on an extracellularly accessible surface of a cancerous cell, the deNAc SA epitope minimally defined by a dimer containing at least one de-N-acetylated sialic acid residue having a free amine adjacent an N-acylated sialic acid residue or a sialic acid derivative residue, wherein:
- the antibody binds to the deNAc SA epitope on the surface of CHP-134 neuroblastoma cells, and
- the antibody competes for binding to the deNAc SA epitope with an antibody comprising:
- a heavy chain polypeptide comprising:
- a VH CDR1 comprising amino acid residues 26 to 35 of SEQ ID NO:7,
- a VH CDR2 comprising amino acid residues 50 to 66 of SEQ ID NO:7,
- a VH CDR3 comprising amino acid residues 101 to 108 of SEQ ID NO:7;
- and
- a light chain polypeptide comprising:
- a VL CDR1 comprising amino acid residues 24 to 39 of SEQ ID NO:3,
- a VL CDR2 comprising amino acid residues 55 to 61 of SEQ ID NO:3, and
- a VL CDR3 comprising amino acid residues 94 to 100 of SEQ ID NO:3;
- and
- a moiety covalently bound to the antibody.
11 more elements
An antibody fusion protein, comprising:
- an antibody that specifically binds a de-N-acetylated sialic acid (deNAc SA) epitope on an extracellularly accessible surface of a cancerous cell, the deNAc SA epitope minimally defined by a dimer containing at least one de-N-acetylated sialic acid residue having a free amine adjacent an N-acylated sialic acid residue or a sialic acid derivative residue, wherein:
- the antibody binds to the deNAc SA epitope on the surface of CHP-134 neuroblastoma cells, and
- the antibody competes for binding to the deNAc SA epitope with an antibody comprising:
- a heavy chain polypeptide comprising:
- a VH CDR1 comprising amino acid residues 26 to 35 of SEQ ID NO:7,
- a VH CDR2 comprising amino acid residues 50 to 66 of SEQ ID NO:7,
- a VH CDR3 comprising amino acid residues 101 to 108 of SEQ ID NO:7;
- and
- a light chain polypeptide comprising:
- a VL CDR1 comprising amino acid residues 24 to 39 of SEQ ID NO:3,
- a VL CDR2 comprising amino acid residues 55 to 61 of SEQ ID NO:3, and
- a VL CDR3 comprising amino acid residues 94 to 100 of SEQ ID NO:3;
- and
- a heterologous polypeptide fused to a terminus of a heavy or light chain polypeptide of the antibody.
11 more elements
Dependencies are inferred from the claim text.